Biopharma Quarterly Dealmaking Statistics, Q3 2016

A look at financing, M&A and alliance activity July–September 2016

In Q3, biopharma financing totaled $7.4 billion, a large proportion of which was by rare disease developers; among the highlights in the $23 billion in M&As was Allergan's buying spree, including two NASH companies. Just over $20 billion went into biopharma alliance dealmaking, and neurology assets attracted many of the dollars.

IV1610_Calendar_1200X675

Third-quarter 2016 biopharma financing totaled $7.4 billion, a 54% increase over Q2’s $4.8 billion. Follow-on public offerings were again the lead financing vehicle, bringing in $3.36 billion – close to half of the aggregate amount raised – led by BioMarin Pharmaceutical Inc.’s $714 million August FOPO [See Deal], along with eight other $100 million-plus offerings. (See Exhibit 1.) The orphan disease-focused biotech will use the proceeds for continued clinical trials of its candidates for various rare genetic blood, metabolic and neuro diseases mostly affecting children. It already has five approved products: Vimizim (elosulfase alpha) for Morquio A syndrome, Naglazyme (galsulfase) for mucopolysaccharidosis VI (MPS VI), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Aldurazyme (laronidase) for MPS I, and Firdapse (amifampridine phosphate) for Lambert-Eaton myasthenic syndrome (LEMS) in adults.

Open Media

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal-Making

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By 

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Deals In Depth: April 2025

 
• By 

Four $1bn+ alliances were penned in April, and one exceeded $2bn.

Deals Shaping The Industry, April 2025

 
• By 

An interactive look at pharma, medtech and diagnostics deals made during April 2025. Data courtesy of Biomedtracker.

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By 

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By 

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By 

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By 

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.